Skip to main content
    H

    Haemonetics Corporation (HAE)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $121.40
    -1.54 (-1.25%)

    Market Cap: $5.60B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Haemonetics Corporation (HAE) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Haemonetics reported revenue of $1.33B for the fiscal year ended Mar 31, 2026, down 2.0% from the year before. That year, net income was $97.31M with a net margin of 7.3%, operating cash flow was $293.22M and free cash flow was $260.44M. The quarter ended Sep 30, 2026 had revenue of $357.76M and net income of $46.30M.

    Revenue and Margins

    The operating margin was 11.7% in the fiscal year ended Mar 2026. Over the 9 years to Mar 2026, revenue grew from $886.12M, a compound annual rate of 4.6%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Mar 2026$1.33B-2.0%59.0%11.7%7.3%
    Mar 2025$1.36B+4.0%55.0%16.3%12.3%
    Mar 2024$1.31B+12.0%52.8%12.6%9.0%
    Mar 2023$1.17B+17.7%52.6%13.4%9.9%
    Mar 2022$993.20M+14.1%50.9%8.1%4.4%
    Mar 2021$870.46M-11.9%45.7%10.3%9.1%
    Mar 2020$988.48M+2.2%49.0%10.5%7.7%
    Mar 2019$967.58M+7.0%43.2%8.6%5.7%
    Mar 2018$903.92M+2.0%45.6%6.2%5.0%
    Mar 2017$886.12MN/A42.7%-2.2%-3.0%
    Annual, fiscal years ended Mar 2017 to Mar 2026

    Income Statement

    In the fiscal year ended Mar 2026, net income fell 42.0% from the year before. In the quarter ended Sep 2026, net income rose 19.7% from the same quarter a year earlier.

    Annual

    Line itemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
    Revenue$1.33B$1.36B$1.31B$1.17B$993.20M$870.46M$988.48M$967.58M$903.92M$886.12M
    Cost of revenue$546.44M$611.87M$617.51M$553.56M$487.69M$472.63M$503.97M$550.04M$492.01M$507.62M
    Gross profit$787.59M$748.96M$691.55M$615.10M$505.50M$397.84M$484.51M$417.54M$411.91M$378.49M
    Research and development$59.77M$62.72M$54.44M$50.13M$46.80M$32.86M$30.88M$35.71M$39.23M$37.56M
    Operating income$156.73M$221.82M$164.88M$156.03M$80.75M$89.75M$103.35M$83.55M$56.16M-$19.38M
    Net income$97.31M$167.68M$117.56M$115.40M$43.38M$79.47M$76.53M$55.02M$45.57M-$26.27M
    EBITDA$245.56M$342.61M$252.43M$234.71M$164.78M$157.76M$198.04M$183.05M$148.88M$62.26M
    Fiscal years ended Mar 2017 to Mar 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$357.76M$339.38M$346.35M$338.97M$327.31M$321.39M$330.60M$348.54M$345.51M$336.17M$343.29M$336.25M
    Gross profit$220.91M$202.80M$198.21M$202.39M$194.74M$192.24M$193.05M$193.55M$187.44M$174.92M$175.91M$177.87M
    Operating income$75.12M$57.46M-$23.02M$67.40M$58.49M$53.87M$71.33M$59.03M$51.70M$39.76M$29.94M$45.98M
    Net income$46.30M$33.01M-$20.15M$44.74M$38.68M$34.03M$57.98M$37.49M$33.83M$38.37M$20.37M$31.24M
    Last 12 quarters

    Balance Sheet

    As of Mar 2026, total debt of $1.22B exceeded cash and equivalents by $979.14M.

    Annual

    Line itemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
    Total assets$2.40B$2.45B$2.20B$1.93B$1.86B$1.82B$1.27B$1.27B$1.24B$1.24B
    Current assets$834.88M$934.98M$768.90M$769.72M$756.03M$693.55M$603.64M$576.12M$521.18M$510.03M
    Cash and equivalents$245.44M$306.76M$178.80M$284.47M$259.50M$192.31M$137.31M$169.35M$180.17M$139.56M
    Total liabilities$1.60B$1.63B$1.24B$1.12B$1.11B$1.09B$680.00M$606.90M$484.91M$499.10M
    Short-term debt$5.01M$303.56M$10.23M$11.78M$214.15M$17.02M$76.98M$27.67M$194.26M$61.02M
    Long-term debt$1.22B$921.23M$797.56M$754.10M$559.44M$690.59M$305.51M$322.45M$59.42M$253.63M
    Shareholder equity$796.32M$820.84M$959.96M$818.00M$749.42M$731.67M$587.11M$667.87M$752.43M$739.61M
    Fiscal years ended Mar 2017 to Mar 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$2.41B$2.37B$2.40B$2.49B$2.44B$2.46B$2.45B$2.53B$2.53B$2.54B$2.20B$2.20B
    Total liabilities$1.51B$1.53B$1.60B$1.58B$1.59B$1.58B$1.63B$1.62B$1.65B$1.64B$1.24B$1.26B
    Cash and equivalents$260.71M$223.38M$245.44M$363.37M$296.43M$292.90M$306.76M$320.85M$299.28M$344.43M$178.80M$193.98M
    Shareholder equity$898.50M$837.10M$796.32M$911.45M$849.17M$882.30M$820.84M$906.86M$878.85M$905.37M$959.96M$943.32M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Mar 2026, free cash flow was 88.8% of operating cash flow. Share repurchases came to 67.2% of it.

    Annual

    Line itemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
    Operating cash flow$293.22M$181.72M$181.75M$273.06M$172.26M$108.81M$158.22M$159.28M$220.35M$159.74M
    Capital expenditures$32.78M$39.28M$38.13M$191.33M$96.51M$37.04M$48.76M$118.96M$74.80M$76.14M
    Free cash flow$260.44M$142.45M$143.63M$81.73M$75.75M$71.77M$109.46M$40.32M$145.55M$83.60M
    Dividends paidN/AN/AN/A$7.02MN/AN/A$12.02M$13.45M$0$0
    Share repurchases$175.00M$225.00M$0$75.00M$0$0$175.00M$160.00M$100.00M$0
    Investing cash flow-$179.55M-$161.90M-$322.39M-$143.79M-$86.34M-$425.44M-$57.18M-$116.15M-$63.04M-$73.31M
    Financing cash flow-$178.46M$108.82M$38.16M-$100.36M-$15.75M$367.45M-$131.21M-$50.63M-$120.64M-$60.41M
    Fiscal years ended Mar 2017 to Mar 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$128.10M$52.32M$70.94M$93.56M$111.32M$17.39M$116.56M$43.77M$48.82M-$27.42M$64.08M-$540.00K
    Capital expenditures$14.77M$7.91M$17.66M$6.35M$5.02M$3.75M$15.64M$8.55M$9.43M$5.66M$6.68M$14.65M
    Free cash flow$113.33M$44.42M$53.28M$87.22M$106.31M$13.64M$100.91M$35.22M$39.39M-$33.08M$57.40M-$15.19M
    Last 12 quarters

    Frequently Asked Questions About HAE

    What is Haemonetics' annual revenue?

    Haemonetics reported revenue of $1.33B for the fiscal year ended Mar 31, 2026.

    How fast is Haemonetics' revenue growing?

    Revenue was down 2.0% for the fiscal year ended Mar 31, 2026 compared with the year before. The compound annual revenue growth rate over 3 years was 4.5%.

    Is Haemonetics profitable?

    Yes. Haemonetics reported net income of $97.31M for the fiscal year ended Mar 31, 2026, with a net margin of 7.3%.

    How much free cash flow does HAE generate?

    For the fiscal year ended Mar 31, 2026, operating cash flow of $293.22M minus capital expenditures of $32.78M produced free cash flow of $260.44M.

    How much debt does Haemonetics have?

    The balance sheet dated Mar 31, 2026 reported long-term debt of $1.22B, short-term debt of $5.01M and cash and equivalents of $245.44M.